Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many general statements align with the provided XYZAL label excerpts (indications, H1 receptor mechanism, somnolence cautions, and some adverse reactions). However, several key dosing/population details and safety items are either incorrect or not supported (notably pediatric dosing-by-weight, onset-within-first-day, renal dosing/monitoring phrasing, avoidance of sedating meds language, and omission of urinal retention and hypersensitivity/other precautions).
Category Scores
Accurate Statements
Levocetirizine hydrochloride is an antihistamine used to relieve allergy symptoms.
12.1 Mechanism of Action: levocetirizine is an antihistamine with effects mediated via selective inhibition of H1 receptors (principal effects).
Levocetirizine hydrochloride syrup is prescribed for allergic rhinitis (hay fever).
1.1 Perennial Allergic Rhinitis: indicated for relief of symptoms associated with perennial allergic rhinitis (children 6 months to 2 years of age).
Levocetirizine blocks histamine H1 receptors.
12.1 Mechanism of Action: principal effects mediated via selective inhibition of H1 receptors.
This reduces symptoms like itching and swelling.
14.2 Chronic Idiopathic Urticaria efficacy described for pruritus severity and total symptom score; and urticaria skin manifestations include pruritus.
For many allergy symptoms, relief can begin within the first day of use.
Common side effects for levocetirizine and related antihistamines can include drowsiness or tiredness.
5.1 Somnolence: somnolence, fatigue, and asthenia reported; 6.1: most common adverse reactions include somnolence, fatigue.
Common side effects can include dry mouth.
6.1 Clinical Trials Experience: most common adverse reactions include dry mouth.
Common side effects can include headache.
Common side effects can include fatigue.
6.1: fatigue is among the most common adverse reactions.
Patients should be cautious with activities that require alertness (like driving) because it can cause drowsiness.
5.1 Somnolence: cautioned against hazardous occupations requiring complete mental alertness, and operating machinery or driving after ingestion.
Alcohol can increase sleepiness with antihistamines.
5.1 Somnolence: concurrent use with alcohol or other CNS depressants should be avoided due to additional reductions in alertness.
Levocetirizine syrup is available in a liquid formulation that allows weight-based dosing.
The exact dose varies by product strength (mg per mL) and the patient’s age.
2.1 and 2.2 dosing specify specific mg doses and corresponding mL (0.5 mg/mL) and age-specific use (e.g., initial dose 1.25 mg; other doses including 2.5 mg/5 mg).
Levocetirizine hydrochloride dosing should follow the specific prescribing label or clinician instructions.
2 Dosage and Administration provides recommended dosing and dose adjustment principles.
Unsupported Statements
Levocetirizine hydrochloride syrup is used for histamine-driven allergy symptoms such as sneezing, runny nose, and itchy/watery eyes.
Provided label excerpts do not mention sneezing, runny nose, or itchy/watery eyes specifically for these indications.
Levocetirizine hydrochloride syrup is used for allergy-related itching.
The provided label supports chronic idiopathic urticaria pruritus severity outcomes, but does not broadly state 'allergy-related itching' beyond that indication.
Levocetirizine hydrochloride syrup is used for allergy-related hives (urticaria).
Label excerpt 1.2 and 2.2 support chronic idiopathic urticaria (uncomplicated skin manifestations), but 'allergy-related hives' is not stated in the provided excerpts.
This improves nasal and eye symptoms.
Provided label excerpts discuss efficacy using reflective total symptom score in perennial allergic rhinitis but do not specifically mention nasal and eye symptoms.
Levocetirizine syrup is commonly used in pediatric patients.
Pediatric use is mentioned in label excerpts (e.g., indications for 6 months to 2 years and 6 months to 17 years), but the claim that it is 'commonly used' is not supported by the provided text.
Levocetirizine syrup is available in a liquid formulation that allows weight-based dosing.
Provided dosing excerpts specify dosing in mg and corresponding mL, with age/renal considerations; they do not describe weight-based dosing.
The correct pediatric dose depends on the patient’s age and weight.
Provided excerpts describe recommended doses by age (and renal impairment rules) but do not state that pediatric dosing depends on weight.
Clinicians consider kidney function in children because antihistamines are cleared partly through the kidneys.
While 8.6 notes substantial excretion by kidneys and 2 includes renal contraindication language, the provided excerpts do not state this rationale 'partly through the kidneys' for children or that clinicians consider kidney function 'because' of clearance in that manner.
Some people may feel more sleepy than others.
Label excerpts do not contain this specific comparative wording (though somnolence varies).
Patients should avoid combining it with other sedating medicines unless a clinician advises it.
Label excerpt 5.1 says concurrent use with alcohol or other CNS depressants should be avoided; it does not say 'unless a clinician advises it.'
For many allergy symptoms, relief can begin within the first day of use.
No onset timeframe is provided in the provided label excerpts.
Symptom control tends to be best when dosing is taken consistently as directed during the allergy period.
No such statement is present in the provided label excerpts.
Dosing is usually based on age (and sometimes weight) and the severity of symptoms.
Provided excerpts describe age-based recommended doses and renal/hepatic adjustments; they do not state dosing is based on severity or that it is 'sometimes' weight-based.
Common side effects can include headache.
Provided label excerpts list common adverse reactions including somnolence, nasopharyngitis, fatigue, dry mouth, and pharyngitis, but do not mention headache.
Other antihistamines (e.g., cetirizine, loratadine, or fexofenadine) may be used as alternatives depending on age, symptoms, and response.
No label excerpt supports use of alternative antihistamines or comparative guidance.
Choice of alternative antihistamine depends on individual tolerance, kidney considerations, and local prescribing preferences.
Not supported in the provided label excerpts.
Patients should avoid combining it with other sedating medicines unless a clinician advises it.
Provided label says to avoid concurrent use with alcohol or other CNS depressants; it does not include conditional 'unless clinician advises'.
Contradictions
Important Omissions
Urinary retention warning and recommendation to use with caution in patients with predisposing factors and discontinue if urinary retention occurs.
Importance:
High
Hypersensitivity contraindication-like precaution: known hypersensitivity to levocetirizine/cetirizine/ingredients.
Importance:
High
Chronic idiopathic urticaria indication is for uncomplicated skin manifestations; 'allergy-related' framing is broader than the label excerpts.
Importance:
Moderate
Renal contraindication: end-stage renal disease patients (CLcr <10 mL/min) and patients undergoing hemodialysis should not receive XYZAL.
Importance:
High
Drug interaction details in label excerpts (e.g., ritonavir and theophylline changes for cetirizine; label excerpts do not support broad statement about 'sedating medicines' beyond CNS depressants and alcohol).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some safety content aligns with label (somnolence counseling, avoid alcohol/CNS depressants). However, omission of urinary retention warning and renal contraindication language, plus unsupported or imprecise statements about dosing basis (age vs weight; weight-based dosing claim) and sedating-medicine guidance, could lead to inaccurate application of the label’s safety requirements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several dosing and safety assertions are unsupported or inconsistent with the provided label excerpts, and important warnings (urinary retention, ESRD/hemodialysis do-not-use) are omitted.
Suggested Improvement
Remove/replace unsupported claims (weight-based dosing, onset within first day, headache as common AE, 'allergy-related itching/hives' broad framing). Add label-supported warnings/precautions: hypersensitivity, urinary retention caution/discontinue, and renal contraindication (ESRD/CLcr <10 mL/min and hemodialysis). Ensure sedating-medicine guidance matches label wording (avoid concurrent use with alcohol/CNS depressants).